title: The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis.
abstract: Epidemiological studies have assessed the association between HIF-1α polymorphisms and cancer risk. However, the results remained conflicting rather than conclusive. Therefore, we performed a systematic review to provide a complete picture and conducted a meta-analysis to derive a precise estimation. We searched PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases until July 2013 to identify eligible studies. Data sets (43) from 39 studies with a total of 10,841 cases and 14,682 controls were included. The most commonly investigated polymorphism was C1772T, followed by G1790A, C111A, and rs2057482. Overall, C1772T and G1790A but not rs2057482 were associated with increased risk for cancer. When stratified by cancer type, C1772T was associated with increased risk for cervical cancer (T/T vs. C/T+C/C: OR = 8.80, 95 % CI = 2.30-33.70), prostate cancer (T vs. C: OR = 1.54, 95 % CI = 1.04-2.30), and other cancers (T vs. C: OR = 1.42, 95 % CI = 1.07-1.89), but not oral, breast, colorectal, endometrial, lung, and bladder cancers or renal cell carcinoma. G1790A was associated with marginal but insignificant risk for prostate cancer (A vs. G: OR = 1.46, 95 % CI = 1.00-2.13, P = 0.056) and with increased risk for oral (A vs. G: OR = 9.66, 95 % CI = 1.31-71.15), lung (A vs. G: OR = 2.27, 95 % CI = 1.74-2.96), and other cancers (A vs. G: OR = 2.06, 95 % CI = 1.26-3.37) and renal cell carcinoma (A/A vs. G/A+G/G: OR = 3.05, 95 % CI = 1.36-6.84), but not breast, colorectal, cervical, or bladder cancer. Furthermore, we detected increased cancer risk in haplotypes TA and CA and in those carrying at least one risk allele, and decreased cancer risk in haplotype TG regarding C1772T and G1790A polymorphisms. Further well-designed studies on various cancer types are warranted to verify our findings.
authors.affiliation: Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Hu
authors.forename: Yuan
authors.initials: Y
authors.lastname: Fang
authors.forename: Jun
authors.initials: J
authors.lastname: Zheng
authors.forename: Yazhou
authors.initials: Y
authors.lastname: He
authors.forename: Xin
authors.initials: X
authors.lastname: Zan
authors.forename: Sen
authors.initials: S
authors.lastname: Lin
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.forename: Hao
authors.initials: H
authors.lastname: Li
authors.forename: Chao
authors.initials: C
authors.lastname: You
mesh_terms: D000483:Alleles; D002681:China; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics*; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D011110:Polymorphism, Genetic; D012307:Risk Factors
chemical_list: C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit
references.citation: Carcinogenesis. 2003 Nov;24(11):1779-83
references.pmid: 12919954
references.citation: Cell. 2001 Oct 5;107(1):1-3
references.pmid: 11595178
references.citation: Science. 2001 Apr 20;292(5516):464-8
references.pmid: 11292862
references.citation: Cancer Detect Prev. 2004;28(2):88-93
references.pmid: 15068831
references.citation: Br J Cancer. 2007 Jan 15;96(1):95-103
references.pmid: 17179985
references.citation: Clin Transl Oncol. 2013 May;15(5):358-63
references.pmid: 22914908
references.citation: Int J Gynecol Cancer. 2011 Jan;21(1):2-7
references.pmid: 21330825
references.citation: Cancer Biol Ther. 2011 Sep 1;12(5):383-7
references.pmid: 21709439
references.citation: Cancer Detect Prev. 2007;31(2):102-9
references.pmid: 17418979
references.citation: Anticancer Res. 2010 Jun;30(6):2393-7
references.pmid: 20651398
references.citation: Nat Rev Cancer. 2003 Oct;3(10):721-32
references.pmid: 13130303
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Transl Res. 2012 Jan;159(1):42-50
references.pmid: 22153809
references.citation: Exp Biol Med (Maywood). 2009 Sep;234(9):1109-16
references.pmid: 19546348
references.citation: Oncol Rep. 2008 Nov;20(5):1181-7
references.pmid: 18949419
references.citation: Sichuan Da Xue Xue Bao Yi Xue Ban. 2010 Jul;41(4):674-7
references.pmid: 20848794
references.citation: Chin J Dig Dis. 2005;6(4):155-8
references.pmid: 16246222
references.citation: Int J Cancer. 2008 Mar 15;122(6):1297-302
references.pmid: 18000826
references.citation: Mol Carcinog. 2010 Sep;49(9):805-9
references.pmid: 20572162
references.citation: PLoS Med. 2009 Jul 21;6(7):e1000097
references.pmid: 19621072
references.citation: Proc Natl Acad Sci U S A. 1993 May 1;90(9):4304-8
references.pmid: 8387214
references.citation: Cell Oncol. 2007;29(3):219-27
references.pmid: 17452774
references.citation: Anticancer Res. 2012 Dec;32(12):5227-32
references.pmid: 23225420
references.citation: Cancer Res. 1999 Nov 15;59(22):5830-5
references.pmid: 10582706
references.citation: J Exp Clin Cancer Res. 2009 Dec 27;28:159
references.pmid: 20035632
references.citation: J Biol Chem. 2001 Jan 19;276(3):2292-8
references.pmid: 11056166
references.citation: Cancer Biol Ther. 2005 Nov;4(11):1222-5
references.pmid: 16205110
references.citation: Genet Test Mol Biomarkers. 2011 Jun;15(6):461-4
references.pmid: 21329466
references.citation: Histopathology. 2008 Apr;52(5):637-9
references.pmid: 18370960
references.citation: BMC Cancer. 2008 Nov 04;8:320
references.pmid: 18983642
references.citation: Genomics. 1996 Jun 15;34(3):437-9
references.pmid: 8786149
references.citation: Arch Med Res. 2008 Apr;39(3):338-45
references.pmid: 18279708
references.citation: Cancer Biol Ther. 2009 Jan;8(2):118-24
references.pmid: 19106642
references.citation: Clin Chim Acta. 2008 Mar;389(1-2):167-70
references.pmid: 18160046
references.citation: Tumori. 2012 May-Jun;98(3):364-9
references.pmid: 22825513
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Surg Oncol. 2010 Aug 1;102(2):163-9
references.pmid: 20648588
references.citation: Oral Oncol. 2009 Dec;45(12):e222-6
references.pmid: 19717330
references.citation: Mol Biol Rep. 2012 Dec;39(12):10873-9
references.pmid: 23065205
references.citation: Mol Carcinog. 2006 Nov;45(11):833-40
references.pmid: 16865676
references.citation: Asian J Androl. 2012 Nov;14(6):864-9
references.pmid: 23042446
references.citation: Ann Surg Oncol. 2009 Aug;16(8):2351-8
references.pmid: 19449077
references.citation: Cell. 2001 Oct 5;107(1):43-54
references.pmid: 11595184
references.citation: J Natl Cancer Inst. 2001 Feb 21;93(4):309-14
references.pmid: 11181778
references.citation: Anticancer Res. 2011 Feb;31(2):575-84
references.pmid: 21378341
references.citation: Br J Oral Maxillofac Surg. 2002 Jun;40(3):191-4
references.pmid: 12054707
references.citation: Oncogene. 2001 Aug 16;20(36):5067-74
references.pmid: 11526493
references.citation: Prostate. 2005 May 15;63(3):215-21
references.pmid: 15538748
references.citation: Prostate. 2007 Jan 1;67(1):8-13
references.pmid: 16998808
references.citation: Biochem Genet. 2009 Oct;47(9-10):625-34
references.pmid: 19504235
references.citation: Respirology. 2011 Jul;16(5):796-802
references.pmid: 21435097
references.citation: Annu Rev Cell Dev Biol. 1999;15:551-78
references.pmid: 10611972
references.citation: Cancer Res. 2000 Sep 1;60(17):4693-6
references.pmid: 10987269
references.citation: Oncol Rep. 2004 Nov;12(5):1033-7
references.pmid: 15492789
references.citation: Physiol Genomics. 2003 Sep 29;15(1):20-6
references.pmid: 12865501
references.citation: Ann Oncol. 2012 Apr;23(4):981-9
references.pmid: 21778301
references.citation: Carcinogenesis. 2010 Aug;31(8):1381-6
references.pmid: 20403915
references.citation: Cancer Genet Cytogenet. 2004 Sep;153(2):122-6
references.pmid: 15350301
references.citation: Tumour Biol. 2013 Oct;34(5):2477-87
references.pmid: 23857282
references.citation: Science. 2001 Apr 20;292(5516):468-72
references.pmid: 11292861
references.citation: Oral Oncol. 2010 Sep;46(9):e47-53
references.pmid: 20656543
references.citation: Biochim Biophys Acta. 2011 Aug;1816(1):1-12
references.pmid: 21338656
references.citation: Neoplasma. 2009;56(5):441-7
references.pmid: 19580347
references.citation: Anticancer Res. 2009 Nov;29(11):4337-43
references.pmid: 20032376
references.citation: Diabetes Care. 2013 Feb;36(2):415-21
references.pmid: 22991450
references.citation: Prostate. 2007 Sep 1;67(12):1354-61
references.pmid: 17624927
references.citation: Am J Pathol. 2000 Aug;157(2):411-21
references.pmid: 10934146
references.citation: Lung Cancer. 2006 Sep;53(3):257-62
references.pmid: 16837101